Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 62
- Registration Number
- NCT00621361
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT00618501
- Locations
- 🇰🇷
Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of
Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors
- Conditions
- Ewing Sarcoma of BoneLocalized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Interventions
- Other: radiation therapyOther: therapeutic conventional surgeryDrug: etoposideDrug: ifosfamideDrug: doxorubicin hydrochlorideDrug: cyclophosphamideDrug: vincristine sulfateDrug: topotecan hydrochlorideBiological: filgrastim
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 35
- Registration Number
- NCT00618813
- Locations
- 🇺🇸
Children's Oncology Group, Monrovia, California, United States
Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
- Conditions
- Lung Cancer
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 41
- Registration Number
- NCT00616785
- Locations
- 🇰🇷
Yonsei Cancer Center at Yonsei University Medical Center, Seoul, Korea, Republic of
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- Associazione Italiana Ematologia Oncologia Pediatrica
- Target Recruit Count
- 2039
- Registration Number
- NCT00613457
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Hoosier Cancer Research Network
- Target Recruit Count
- 74
- Registration Number
- NCT00613626
- Locations
- 🇺🇸
Helen F. Graham Cancer Center, Newark, Delaware, United States
🇺🇸Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
🇺🇸Cancer Care Center of Southern Indiana, Bloomington, Indiana, United States
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
- Conditions
- Recurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Hodgkin LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular Lymphoma
- Interventions
- Drug: vorinostatBiological: rituximabDrug: ifosfamideDrug: carboplatinDrug: etoposideOther: pharmacological studyOther: laboratory biomarker analysisGenetic: gene expression analysis
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 29
- Registration Number
- NCT00601718
- Locations
- 🇺🇸
Puget Sound Oncology Consortium, Seattle, Washington, United States
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
- Conditions
- Adult Acute Monoblastic Leukemia (M5a)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Secondary Acute Myeloid LeukemiaAdult Acute Myelomonocytic Leukemia (M4)Untreated Adult Acute Myeloid LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monocytic Leukemia (M5b)
- Interventions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 84
- Registration Number
- NCT00602771
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: rituximabDrug: bortezomibDrug: carboplatinDrug: dexamethasoneDrug: etoposideDrug: ifosfamideGenetic: polymerase chain reactionGenetic: western blotting
- First Posted Date
- 2008-01-18
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- AIDS Malignancy Consortium
- Target Recruit Count
- 23
- Registration Number
- NCT00598169
- Locations
- 🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇺🇸UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
- Conditions
- LymphomaDiffuse Large Cell Lymphoma
- Interventions
- Drug: ZevalinDrug: CarmustineDrug: EtoposideDrug: CytarabineDrug: MelphalanDrug: RituximabProcedure: Stem Cell Transplant
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00591630
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.